MAP2K7 and neoplasm: The plasticity of adaptive signaling, the different ways in which signaling kinases are coupled to cell state and phenotype, and the fact that we did not observe strong positive and negative correlations between different pathways raise the question of whether every cell line (or patient tumor) adapts differently to the anti-mitogenic effects of MEK or BRAFV600E inhibition.